Cantor Fitzgerald Reaffirms Overweight Rating for Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $67.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 149.91% from […]
More Stories
Financial Contrast: CardioGenics (OTCMKTS:CGNH) vs. Accolade (NASDAQ:ACCD)
Accolade (NASDAQ:ACCD – Get Free Report) and CardioGenics (OTCMKTS:CGNH – Get Free Report) are both business services companies, but which...
Arm Holdings plc (NASDAQ:ARM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Arm Holdings plc (NASDAQ:ARM – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-seven...
Comparing Banner (NASDAQ:BANR) and CVB Financial (NASDAQ:CVBF)
CVB Financial (NASDAQ:CVBF – Get Free Report) and Banner (NASDAQ:BANR – Get Free Report) are both mid-cap finance companies, but...
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Buy” by Analysts
Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) have received a consensus rating of “Buy” from the ten...
i-80 Gold Corp. (NYSE:IAUX) Receives Consensus Rating of “Hold” from Brokerages
Shares of i-80 Gold Corp. (NYSE:IAUX – Get Free Report) have received a consensus recommendation of “Hold” from the four...
Itaú Unibanco (NYSE:ITUB) & Eagle Financial Services (OTCMKTS:EFSI) Head-To-Head Review
Itaú Unibanco (NYSE:ITUB – Get Free Report) and Eagle Financial Services (OTCMKTS:EFSI – Get Free Report) are both finance companies,...